Yixintang Pharmaceutical Group Co., Ltd.

Symbol: 002727.SZ

SHZ

18.75

CNY

Market price today

  • 23.9311

    P/E Ratio

  • 0.6980

    PEG Ratio

  • 11.17B

    MRK Cap

  • 0.02%

    DIV Yield

Yixintang Pharmaceutical Group Co., Ltd. (002727-SZ) Financial Statements

On the chart you can see the default numbers in dynamics for Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Yixintang Pharmaceutical Group Co., Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009

balance-sheet.row.cash-and-short-term-investments

03895.335202532.4
1624
1459.5
1351.9
2196
1594.7
1033.9
1056.3
520.4
386.1
386.5
378.6
216.6

balance-sheet.row.short-term-investments

0219.78.4297.3
-552.1
-493.9
81
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

01991.724111777.5
1422.5
1160.9
1192.1
1160.8
1100.1
907.4
660.4
562
404.9
303.9
256.5
195.4

balance-sheet.row.inventory

03852.63387.43317
2194.5
2028
1866
1626.3
1373.4
1024.3
766.4
608
448.7
401.1
316.9
212.6

balance-sheet.row.other-current-assets

0153.3139.265.5
1477.1
959.3
646.9
13.1
325.1
48
-84.2
-65.5
-47.5
-38.1
-35.5
-24.4

balance-sheet.row.total-current-assets

09892.99457.67692.4
6718
5607.8
5056.8
4996.2
4393.4
3013.6
2398.9
1625
1192.3
1053.4
916.6
600.2

balance-sheet.row.property-plant-equipment-net

03995.63993.54080
690.5
585.6
535.6
509.3
497.4
474.1
412.1
345.3
271.8
210
150.7
53.8

balance-sheet.row.goodwill

01649.61397.21380
1102.2
1061.1
1077.1
1057.7
796
497
1.5
0
0
0
0
0

balance-sheet.row.intangible-assets

0184.1165.7122.9
122.9
90.5
84.7
82.7
88.1
62
29.3
14.7
15.5
16.3
13.1
14.8

balance-sheet.row.goodwill-and-intangible-assets

01833.71562.91502.8
1225.1
1151.6
1161.8
1140.4
884.2
559
30.9
14.7
15.5
16.3
13.1
14.8

balance-sheet.row.long-term-investments

0165.3131.4-190.1
635.7
577.4
0
0
176.4
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

088.994.158.5
27.6
22.4
28.9
45
49.8
42.8
30.2
25.4
13.6
5.9
2.5
1.3

balance-sheet.row.other-non-current-assets

0670.8939.51193.8
31.4
18.1
572.6
455.7
12
96.8
69.4
62.5
31.3
22.7
21.9
15.3

balance-sheet.row.total-non-current-assets

06754.56721.56645
2610.3
2355
2299
2150.4
1619.8
1172.6
542.6
447.8
332.1
254.9
188.1
85.2

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

016647.416179.114337.3
9328.3
7962.8
7355.9
7146.6
6013.2
4186.3
2941.4
2072.8
1524.4
1308.3
1104.7
685.4

balance-sheet.row.account-payables

02560.24328.83805.9
2875.8
2316.1
2031.9
1699.7
1513.7
1065.7
722.7
680.1
493.4
449.4
373.9
237.7

balance-sheet.row.short-term-debt

03333.91335.51143.9
60.1
0
798.9
100
0.7
625
0
220
156
195.3
180.2
110.8

balance-sheet.row.tax-payables

081.4250.4164.1
105.8
129.3
158.1
146.1
22
52
27.4
28.7
14.5
8.9
27.9
24

balance-sheet.row.long-term-debt-total

01552.21758.51764.1
1795.5
482.8
0
796.5
794.2
0
0
0
0
3.3
3.3
6.8

Deferred Revenue Non Current

01.212.213.3
15.8
39.2
17.2
13.6
10
6.4
3
3.2
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

01191.91055.812.7
8.6
74.1
458.3
842.8
804.9
4.4
133.1
8.2
4.5
1.6
0.6
0.5

balance-sheet.row.total-non-current-liabilities

01557.31774.71781
15.8
540.2
17.2
810.2
804.3
6.4
3
3.2
2.2
5.3
5.3
6.8

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

01552.21756.71729
1795.5
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

08757.18651.57664.8
3547.8
3366.6
3306.4
3452.7
3515.1
1913.3
858.7
1022.7
713.6
679.5
607.3
422.6

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

0596596596.2
595.3
567.8
567.8
567.8
520.6
260.3
260.3
195.2
195.2
195.2
195.2
175.7

balance-sheet.row.retained-earnings

04646.44335.43504.2
2834.4
2268.4
1876.3
1561.7
1272.7
1074.5
906.4
627.7
405.1
237.1
113.3
49.3

balance-sheet.row.accumulated-other-comprehensive-income-loss

0377.8424.9405.6
279.8
356.6
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

02125.82069.82071.7
2056
1402.2
1601.5
1564.5
703.1
938.2
916
224.3
206.1
191.5
181
33.2

balance-sheet.row.total-stockholders-equity

077467426.16577.7
5765.4
4594.9
4045.6
3693.9
2496.4
2273
2082.7
1047.2
806.4
623.8
489.5
258.2

balance-sheet.row.total-liabilities-and-stockholders-equity

016647.416179.114337.3
9328.3
7962.8
7355.9
7146.6
6013.2
4186.3
2941.4
2072.8
1524.4
1308.3
1104.7
685.4

balance-sheet.row.minority-interest

0131101.494.8
15.1
1.2
4
0
1.8
0
0
2.9
4.4
5
8
4.6

balance-sheet.row.total-equity

078777527.66672.5
5780.5
4596.2
4049.5
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

0385139.8107.2
83.6
83.5
81
12
176.4
0
3.9
3.4
2.9
2.7
2.7
2.5

balance-sheet.row.total-debt

04886.130942908
60.1
482.8
798.9
896.5
794.9
625
0
220
156
198.5
180.2
110.8

balance-sheet.row.net-debt

01210.5-417.6672.9
-1564
-976.7
-553
-1299.5
-799.8
-408.9
-1056.3
-300.4
-230.1
-188
-198.3
-105.8

Cash Flow Statement

The financial landscape of Yixintang Pharmaceutical Group Co., Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009

cash-flows.row.net-income

0549.41013917.2
789.2
603.3
519.8
422.7
353.6
346.4
295
239.4
182
132.8
102.9
84.8

cash-flows.row.depreciation-and-amortization

001000.61087.8
79.8
73.4
74.4
72.9
66.6
51.5
37.4
24.7
22.3
19.3
0
0

cash-flows.row.deferred-income-tax

00-35.1-27.3
-23.4
3.4
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0014.240.4
32.4
-3.4
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

00-9.7-603.9
30.6
114.1
-49.1
-256.2
-234
-340.5
-214
-87.9
-83.6
-81.8
0
0

cash-flows.row.account-receivables

00-765.8-739.7
-279.4
40.8
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

00-234.9-1236.8
-237.1
-206.1
-229.8
-333.8
-386
-304.3
-167.7
-165.9
-48.6
-83.9
0
0

cash-flows.row.account-payables

001026.11399.9
570.5
276
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

00-35.1-27.3
-23.4
3.4
180.7
77.6
151.9
-36.2
-46.3
78
-35
2.2
0
0

cash-flows.row.other-non-cash-items

0-549.4514.1377.5
124.9
192.1
90.7
151.7
6.5
128.3
57.8
52
37
31.2
-102.9
-84.8

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

00-349-391.6
-280.2
-206.9
-156
-142
-146.1
-194
-158.6
-145.4
-103.8
-97.6
-139.6
-26.9

cash-flows.row.acquisitions-net

00-4.7-65.1
3.4
1.4
-11.6
-3.5
-47.3
0
0.4
0
0
0
1.2
0

cash-flows.row.purchases-of-investments

00-980.5-1976.5
-5195
-3320.9
-3015.5
-250.7
-390
-506.7
-6.9
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

001207.22901.8
4728.6
3022.1
2358.2
518
125
12
159
0
0
0
0
0

cash-flows.row.other-investing-activites

00-94.7-336.9
-181.5
-52.7
-69.3
-407.3
-210.5
-66.5
-158.6
0.1
0.6
0.3
8.3
4.8

cash-flows.row.net-cash-used-for-investing-activites

00-221.7131.7
-924.7
-556.8
-894.3
-285.6
-668.9
-755.2
-164.7
-145.3
-103.2
-97.3
-130.1
-22.1

cash-flows.row.debt-repayment

00-207.9-137.1
-51.1
-800
-514
-850.7
-532.1
-83
-320
-186
-349.5
-282.9
-249
-111.8

cash-flows.row.common-stock-issued

0020.1
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

00-2-0.1
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

00-191.6-180.9
-175
-200.3
-211.6
-168.5
-133.9
-166.4
-8.6
-12.5
-12.4
-10.6
-35.4
-4.9

cash-flows.row.other-financing-activites

00-678.6-986.8
177.6
596.9
5.3
1462
1591.3
708
849
250
307
297.2
469.5
173.8

cash-flows.row.net-cash-used-provided-by-financing-activities

00-1078.2-1304.8
-48.4
-403.3
-720.4
442.8
925.4
458.6
520.5
51.5
-55
3.7
185.1
57.1

cash-flows.row.effect-of-forex-changes-on-cash

000.3-0.1
-0.2
0.1
0.5
-0.1
0.1
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

001197.5618.5
60
22.8
-978.4
548.3
449.1
-110.9
531.9
134.4
-0.5
8
161.9
90.3

cash-flows.row.cash-at-end-of-period

02859.52859.51661.9
1043.5
983.4
960.6
1939
1390.7
941.5
1052.4
520.4
386.1
386.5
378.6
216.6

cash-flows.row.cash-at-beginning-of-period

02859.51661.91043.5
983.4
960.6
1939
1390.7
941.6
1052.4
520.4
386.1
386.5
378.6
216.6
126.3

cash-flows.row.operating-cash-flow

002497.11791.7
1033.4
982.9
635.8
391.2
192.6
185.8
176.2
228.2
157.7
101.6
0
0

cash-flows.row.capital-expenditure

00-349-391.6
-280.2
-206.9
-156
-142
-146.1
-194
-158.6
-145.4
-103.8
-97.6
-139.6
-26.9

cash-flows.row.free-cash-flow

002148.11400
753.2
776.1
479.7
249.1
46.5
-8.3
17.6
82.8
53.9
4
-139.6
-26.9

Income Statement Row

Yixintang Pharmaceutical Group Co., Ltd.'s revenue saw a change of NaN% compared with the previous period. The gross profit of 002727.SZ is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009

income-statement-row.row.total-revenue

017301.417431.614587.4
12656.3
10479.1
9176.3
7751.1
6249.3
5321.2
4428.4
3546.7
2842.1
2218.5
1850.2
1456

income-statement-row.row.cost-of-revenue

011750.311322.39196.5
8123
6424.1
5457
4532.5
3669.4
3090.3
2637.8
2142.5
1758
1355.9
1159.9
925

income-statement-row.row.gross-profit

055516109.35390.9
4533.3
4055
3719.2
3218.6
2579.9
2230.9
1790.6
1404.2
1084.2
862.6
690.2
531

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0-106.6349.1320.6
437.6
343.3
414.3
367.8
18.5
12.8
2.4
6.4
6.3
2
2.4
-4.5

income-statement-row.row.operating-expenses

04717.54496.84091.3
3558.9
3250.3
2924.5
2574.6
2110.1
1791.6
1386.7
1117.6
867.4
694.5
559.8
414.5

income-statement-row.row.cost-and-expenses

016467.815819.113287.8
11681.9
9674.4
8381.5
7107.2
5779.5
4881.9
4024.5
3260.1
2625.4
2050.4
1719.7
1339.4

income-statement-row.row.interest-income

0-77.653.439.2
24.2
19
12.4
10.7
12.2
13.6
8.6
6.3
4.9
4
0
0

income-statement-row.row.interest-expense

0135.3147.1136.2
24.5
33.7
47.6
57.6
37.5
20.4
8.1
12.9
12.4
10
4.8
6

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0-123.6-426.928.6
39
9.8
7.3
-140.5
-60.4
-49.1
-58.6
-16.6
-11.9
-10.2
-4.6
-11.8

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0-106.6349.1320.6
437.6
343.3
414.3
367.8
18.5
12.8
2.4
6.4
6.3
2
2.4
-4.5

income-statement-row.row.total-operating-expenses

0-123.6-426.928.6
39
9.8
7.3
-140.5
-60.4
-49.1
-58.6
-16.6
-11.9
-10.2
-4.6
-11.8

income-statement-row.row.interest-expense

0135.3147.1136.2
24.5
33.7
47.6
57.6
37.5
20.4
8.1
12.9
12.4
10
4.8
6

income-statement-row.row.depreciation-and-amortization

01332.41000.61397.7
229.8
184.9
222.4
72.9
66.6
51.5
37.4
24.7
22.3
19.3
8.7
8.5

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

0833.51661.91067.9
917.9
739.2
684.3
687.4
392.6
379
344.4
264.3
198.9
156.3
123.9
109.8

income-statement-row.row.income-before-tax

0709.912351096.5
956.9
749.1
691.7
546.9
409.4
390.1
345.3
269.9
204.8
157.9
125.9
104.8

income-statement-row.row.income-tax-expense

0142.2222179.3
167.7
145.7
171.9
124.1
55.8
43.7
50.3
30.6
22.9
25.1
24.4
20

income-statement-row.row.net-income

0549.41010921.6
790
603.9
521.1
422.7
353.4
346.4
297.3
240.9
182.6
134.7
102.9
84.8

Frequently Asked Question

What is Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) total assets?

Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) total assets is 16647375283.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 0.318.

What is company free cash flow?

The free cash flow is 3.367.

What is enterprise net profit margin?

The net profit margin is 0.031.

What is firm total revenue?

The total revenue is 0.045.

What is Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) net profit (net income)?

The net profit (net income) is 549441525.000.

What is firm total debt?

The total debt is 4886107552.000.

What is operating expences number?

The operating expences are 4717493463.000.

What is company cash figure?

Enretprise cash is 0.000.